United States (USA) (US)

COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis (2022) Naveen R, Parodis I, Joshi M, Sen P, Kim M, Agarwal V, Kardes S, et al. Conference contribution COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey (2022) Dey M, Naveen R, Nikiphorou E, Sen P, Lilleker JB, Agarwal V, Kardes S, et al. Conference contribution Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naive Adults with PsA (2022) Siebert S, Schett G, Raychaudhuri SP, Guma M, Chen W, Gao S, Chakravarty S, et al. Conference contribution Anterior Knee Pain Is Associated with 2-year Compartment Specific Patellofemoral Cartilage Worsening: The MOST Study (2022) Lanois C, Collins N, Neogi T, Guermazi A, Roemer F, Lavalley M, Nevitt M, et al. Conference contribution Three-dimensional Ground Reaction Force Symmetry Metrics Largely Fail to Explain Cartilage Worsening in the Contralateral Knee in Persons with Unilateral Knee Osteoarthritis: The Multicenter Osteoarthritis Study (2022) Corrigan P, Lewis C, Costello K, Guermazi A, Roemer F, Kumar D, Felson D, et al. Conference contribution Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast (2022) Mease PJ, Gladman D, Schett G, Paris M, Cheng S, Richter S, Teng L, Kavanaugh A Conference contribution Accelerating AxSpA Diagnosis: Exploring At-home Self-sampling, Symptom Checkers, Medical Student-visits and Asynchronous Reportbased Assessment (2022) Labinsky H, Von Rohr S, Raimondo MG, Vogt E, Horstmann B, Gehring I, Rojas-Restrepo J, et al. Conference contribution HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours (2022) Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Heudobler D, Borchmann P, et al. Conference contribution Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis (2022) Cortes J, Haiderali A, Huang M, Pan W, Fox GE, Park J, Frederickson AM, et al. Conference contribution